BiotechTV - News

He talks about KRAS degraders, claudin 18.2, AAV gene therapy, and more. Plus, how Astellas thinks about the coming patent expiry of Xtandi.

He describes the launch, physician and patient feedback, and responds in his own words to short seller criticism.

He discusses the rationale behind acquiring a DGAT-2 and GLP-1, and how a non-pharma sized company has been able to succeed with a new drug launch.

He discusses the $145M 4Q number that was announced at JPM, and the real world feedback the company has been receiving from physicians and patients. Plus, how the thinks about Insmed now that it is a $35B market cap company.

John Evans, CEO of Beam Therapeutics, shares exciting advancements in base editing therapies for genetic diseases. He discusses potential accelerated approval for alpha-1 antitrypsin deficiency, highlighting regulatory feedback and a focus on confirmatory trials measuring lung and liver outcomes. Evans explains the advantages of base editing over other methods, especially for sickle cell disease, and teases future targets for liver conditions. With innovative approaches to LNP delivery, he emphasizes the platform's potential for customizable solutions in genetic therapies.

Noubar Afeyan, co-founder of Flagship Pioneering and a pivotal figure in Moderna, shares his insights on the importance of defending the scientific method in today’s society. He emphasizes the need to engage the public in science through compelling narratives. Afeyan dives into the transformative potential of mRNA technology, its delivery innovations, and the resurgence of biotech investing post-pandemic. Additionally, he discusses Flagship's investments in AI and the future of scientific research, highlighting the intersection of technology and biology.

Brian Skorney, a senior biotech analyst at Baird, dives into the latest trends from San Francisco Healthcare Week. He highlights Biohaven's innovative degrader platform and its potential impact on IGAN treatment. Skorney also discusses Xenon's KV7 program, emphasizing its promising efficacy in seizure management. He identifies Biogen as a key player due to its advancements in blood biomarkers and dosing methods. Lastly, he reviews the ongoing developments at Sarepta and their gene therapy strategies. Tune in for insightful market perspectives!

Marshall Fordyce, Founder and CEO of Vera Therapeutics, dives into the groundbreaking potential of atacicept for treating IgA nephropathy. He discusses the impressive FDA acceptance of their BLA filing and the important role of Phase III data published in NEJM. Fordyce explains how atacicept uniquely targets BAFF and APRIL to reduce immune complexes and improve treatment outcomes. As they prepare for a commercial launch, he highlights patient-friendly dosing options and clear communication with the FDA.

Vlad Coric, Chairman and CEO of Biohaven and an expert in neurology and immunology, dives into the company’s innovative pipeline. He highlights the degrader programs targeting immunology and discusses a brain-penetrant TYK2/JAK1 inhibitor for Parkinson's. Coric also shares insights about a myostatin approach to tackle obesity and preserve muscle, and the promising Kv7 epilepsy program, emphasizing upcoming trial data. His commitment to ataxia patients and navigating FDA challenges adds depth to this engaging conversation.

In this engaging discussion, Marc de Garidel, CEO of Abivax, shares insights into the promising future of obefazimod, highlighting key 2025 data and plans for 2026. He emphasizes the importance of upcoming clinical data for ulcerative colitis and Crohn's disease. Marc also addresses market pressures and M&A speculation while reassuring listeners about the safety profiles observed in trials. He describes obefazimod's unique mechanism as an immunostabilizer, offering hope for patients and optimism for forthcoming results related to fibrosis and TH17 effects.